OncoMatch/Clinical Trials/NCT05757219
Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy
Is NCT05757219 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Chimeric antigen receptor (CAR) T-cell therapy and Itacitinib for diffuse large b cell lymphoma.
Treatment: Itacitinib · Chimeric antigen receptor (CAR) T-cell therapy — The purpose of the study is to assess the safety and efficacy of once daily itacitinib oral administration in participants with diffuse large B-cell lymphoma (DLBCL) who will receive CAR-T cell therapy with axicabtagene ciloleucel (axi-cel).
Check if I qualifyExtracted eligibility criteria
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: CAR-T cell therapy
Prior treatment with chimeric antigen receptor (CAR) T-cell therapy
Cannot have received: investigational agent
currently receiving or who have received any investigational study agent ≤4 weeks prior to screening visit
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Moffitt Cancer Center · Tampa, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify